Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells

被引:30
|
作者
Andreasson, Ulrika [1 ,2 ]
Dictor, Michael [3 ]
Jerkeman, Mats [2 ,4 ]
Berglund, Mattias [5 ]
Sundstrom, Christer [6 ,7 ]
Linderoth, Johan [4 ]
Rosenquist, Richard [6 ,7 ]
Borrebaeck, Carl A. K. [1 ,2 ]
Ek, Sara [1 ,2 ]
机构
[1] Lund Univ, Dept Immunotechnol, Lund, Sweden
[2] Lund Univ, CREATE Hlth, Lund, Sweden
[3] Univ Lund Hosp, Dept Pathol, S-22184 Lund, Sweden
[4] Univ Lund Hosp, Dept Oncol, S-22184 Lund, Sweden
[5] Uppsala Univ, Dept Oncol Radiol & Clin Immunol, Uppsala, Sweden
[6] Uppsala Univ, Dept Genet, Uppsala, Sweden
[7] Uppsala Univ, Dept Pathol, Uppsala, Sweden
关键词
NON-HODGKINS-LYMPHOMAS; HIGHER GRADE TRANSFORMATION; FOLLICLE CENTER LYMPHOMA; GENE-EXPRESSION; KAPPA-B; GALECTIN-3; PATTERNS; SURVIVAL; MICROENVIRONMENT; PROGRESSION;
D O I
10.1002/ajh.21549
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Follicular lymphoma (FL) frequently transforms into the more aggressive diffuse large B cell lymphoma (DLBCL-tr), but no protein biomarkers have been identified for predictive or early diagnosis. Gene expression analyses have identified genes changing on transformation but have failed to be reproducible in different studies, reflecting the heterogeneity within the tumor tissue and between tumor samples. Gene expression analyses on Affymetrix Human Genome U133 Plus 2.0 arrays were performed, using flow cytometry sorted tumor cells derived from FL and transformed DLBCL. To identify molecular targets associated with the transformation, subsequent immunohistochemistry (IHC) analyses of the corresponding proteins were performed. Using highly purified cells, this study identified 163 genes, which were significantly deregulated during the transformation in a majority of cases. Among the upregulated transcripts, 13 genes were selected for validation using IHC, based on the availability of commercial antibodies, and galectin-3 and NEK2 proteins specifically identify DLBCL-tr, when compared with FL. We demonstrate that by purifying tumor cells through cell sorting, thereby reducing the heterogeneity due to infiltrating cells, it was possible to identify distinct differences between tumor entities rather than variations due to cellular composition. Galectin-3 and NEK2 both identified a subgroup of DLBCL-tr, and the function of these protein markers also suggests a biological role in the transformation process. Am. J. Hematol. 84:803-808, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:803 / 808
页数:6
相关论文
共 50 条
  • [41] B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma
    Ci, Weimin
    Polo, Jose M.
    Melnick, Ari
    CURRENT OPINION IN HEMATOLOGY, 2008, 15 (04) : 381 - 390
  • [42] Impact of Tumor Infiltrating T Cells in Patients with Diffuse Large B-Cell Lymphoma
    Kiaii, Shahryar
    Clear, Andrew James
    Gribben, John G.
    BLOOD, 2012, 120 (21)
  • [43] The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
    Steen, Chloe
    Luca, Bogdan
    Esfahani, Mohammad
    Azizi, Armon
    Sworder, Brian
    Nabet, Barzin
    Kurtz, David
    Liu, Chih
    Khameneh, Farnaz
    Advani, Ranjana
    Natkunam, Yasodha
    Myklebust, June
    Diehn, Maximilian
    Gentles, Andrew
    Newman, Aaron
    Alizadeh, Ash
    CANCER CELL, 2021, 39 (10) : 1422 - +
  • [44] Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma
    Goldstein, Rebecca L.
    Yang, Shao Ning
    Taldone, Tony
    Chang, Betty
    Gerecitano, John
    Elenitoba-Johnson, Kojo
    Shaknovich, Rita
    Tam, Wayne
    Leonard, John P.
    Chiosis, Gabriela
    Cerchietti, Leandro
    Melnick, Ari
    JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (12): : 4559 - 4571
  • [45] Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
    Chapuy, Bjoern
    Stewart, Chip
    Dunford, Andrew J.
    Kim, Jaegil
    Kamburov, Atanas
    Redd, Robert A.
    Lawrence, Mike S.
    Roemer, Margaretha G. M.
    Li, Amy J.
    Ziepert, Marita
    Staiger, Annette M.
    Wala, Jeremiah A.
    Ducar, Matthew D.
    Leshchiner, Ignaty
    Rheinbay, Ester
    Taylor-Weiner, Amaro
    Coughlin, Caroline A.
    Hess, Julian M.
    Pedamallu, Chandra S.
    Livitz, Dimitri
    Rosebrock, Daniel
    Rosenberg, Mara
    Tracy, Adam A.
    Horn, Heike
    van Hummelen, Paul
    Feldman, Andrew L.
    Link, Brian K.
    Novak, Anne J.
    Cerhan, James R.
    Habermann, Thomas M.
    Siebert, Reiner
    Rosenwald, Andreas
    Thorner, Aaron R.
    Meyerson, Matthew L.
    Golub, Todd R.
    Beroukhim, Rameen
    Wulf, Gerald G.
    Ott, German
    Rodig, Scott J.
    Monti, Stefano
    Neuberg, Donna S.
    Loeffler, Markus
    Pfreundschuh, Michael
    Truemper, Lorenz
    Getz, Gad
    Shipp, Margaret A.
    NATURE MEDICINE, 2018, 24 (05) : 679 - +
  • [46] Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
    Graf, Solomon A.
    Cassaday, Ryan D.
    Morris, Karolyn
    Voutsinas, Jenna M.
    Wu, Qian Vicky
    Behnia, Sanaz
    Lynch, Ryan C.
    Krakow, Elizabeth
    Rasmussen, Heather
    Chauncey, Thomas R.
    Kanan, Sandra
    Soma, Lorinda
    Smith, Stephen D.
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 176 - 181
  • [47] Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance
    Bock, Allison M.
    Wenzl, Kerstin
    Novak, Joseph P.
    Stokes, Matthew E.
    Hopper, Melissa A.
    Krull, Jordan E.
    Dropik, Abigail R.
    Sarangi, Vivek
    Ortiz, Maria
    Stong, Nicholas
    Huang, C. Chris
    Maurer, Matthew J.
    King, Rebecca L.
    Farooq, Umar
    Wang, Yucai
    Witzig, Thomas E.
    Ansell, Stephen M.
    Habermann, Thomas M.
    Cerhan, James R.
    Gandhi, Anita K.
    Nowakowski, Grzegorz
    Novak, Anne J.
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
  • [48] Diffuse large B-cell lymphoma: new targets and novel therapies
    Bruce D. Cheson
    Grzegorz Nowakowski
    Gilles Salles
    Blood Cancer Journal, 11
  • [49] A composite lymphoma combining a Hodgkin lymphoma and a marginal zone lymphoma transformed into a diffuse large B-cell lymphoma
    Auditeau, Claire
    Lambotte, Olivier
    Feriel, Joffrey
    Lazure, Thierry
    Turhan, Ali
    Aumont, Cedric
    CLINICAL CASE REPORTS, 2018, 6 (12): : 2341 - 2346
  • [50] Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma
    Klapper, Wolfram
    Kreuz, Markus
    Kohler, Christian W.
    Burkhardt, Birgit
    Szczepanowski, Monika
    Salaverria, Itziar
    Hummel, Michael
    Loeffler, Markus
    Pellissery, Shoji
    Woessmann, Wilhelm
    Schwaenen, Carsten
    Truemper, Lorenz
    Wessendorf, Swen
    Spang, Rainer
    Hasenclever, Dirk
    Siebert, Reiner
    BLOOD, 2012, 119 (08) : 1882 - 1887